Organisation paid for research Program year 2025 Source: CMS Open Payments

Institute for Neurodegenerative Disorders

Neither a doctor nor a teaching hospital

Research payments

$10,417,695

206 payments

Through program year 2025, Institute for Neurodegenerative Disorders is reported as receiving $10,417,695 in research payments, across 206 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$166,318	8
2024	Research	$1,278,350	35
2023	Research	$1,602,782	36
2022	Research	$2,762,293	30
2021	Research	$1,379,300	32
2020	Research	$2,224,192	51
2019	Research	$1,004,459	14

Breakdown

Who paid Research payments · program years 2019–2025

Eli Lilly and Company $5,297,346 36 payments
Roche TCRC, Inc. $1,850,881 63 payments
Biogen, Inc. $1,546,233 5 payments
Genentech, Inc. $1,422,698 99 payments
Ucb SA $300,537 3 payments

Studies the money was for Research payments · program years 2019–2025

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $2,806,957 8 payments
Phase II Study in Early Stage Parkinson S Disease Patients $1,850,881 63 payments
A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $691,447 2 payments
Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease $671,178 2 payments
221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease $627,783 2 payments
Phase II Study of Anti Tau in Prodromal to Mild Ad $606,283 25 payments
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-Avwa in Participants With Early Symptomatic Alzheimer's Disease $541,037 4 payments
Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $480,716 4 payments
Phase II Study for Moderate Ad $417,694 48 payments
A Phase 2B Efficacy Safety Trial of Prasinezumab in Patients With Early Parkinson S Disease $302,486 18 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.